881.4000 -8.95 (-1.01%)
NSE Sep 08, 2025 15:31 PM
Volume: 109.3K
 

881.40
-1.01%
Axis Direct
Regulated markets sales (78% of sales) grew 29% YoY/ 16% QoQ on strong growth in US (over 20% YoY) and steady growth in Australia (high single digit). However, Emerging markets sales (22% of sales) declined 39% YoY/ 38% QoQ due to API supply chain disruption, pricing issues in the ARV portfolio
Promoters unpledged 1.88% of shares in last quarter. Total pledge stands at 50.10% of promoter holdings
More from Strides Pharma Science Ltd.
Recommended